Background Therapy in Salvage Trials
The heterogeneity of previous treatment regimens makes it impossible to construct a single background therapy ( i.e. like nucleosides in a PI trial) for all patients
We feel it is important that any background therapy needs to be flexible, and individually optimized, using phenotypic and genotypic resistance.
Preservation of future treatment options, primary and background, should always be a strong consideration, and might even make a useful secondary endpoint.